Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts also recently issued reports about the stock. Wedbush dropped their price objective […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $76.67 Consensus Price Target from Analysts wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
AGF Management Ltd. Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Apellis stock price slid 10% despite 'robust' growth of Syfovre fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]
Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Price Target at $78.60 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.